Pentavalent HIV-1 vaccine protects against simian-human immunodeficiency virus challenge.
The RV144 Thai trial HIV-1 vaccine of recombinant poxvirus (ALVAC) and recombinant HIV-1 gp120 subtype B/subtype E (B/E) proteins demonstrated 31% vaccine efficacy. Here we design an ALVAC/Pentavalent B/E/E/E/E vaccine to increase the diversity of gp120 motifs in the immunogen to elicit a broader antibody response and enhance protection. We find that immunization of rhesus macaques with the pentavalent vaccine results in protection of 55% of pentavalent-vaccine-immunized macaques from simian-human immunodeficiency virus (SHIV) challenge. Systems serology of the antibody responses identifies plasma antibody binding to HIV-infected cells, peak ADCC antibody titres, NK cell-mediated ADCC and antibody-mediated activation of MIP-1β in NK cells as the four immunological parameters that best predict decreased infection risk that are improved by the pentavalent vaccine. Thus inclusion of additional gp120 immunogens to a pox-prime/protein boost regimen can augment antibody responses and enhance protection from a SHIV challenge in rhesus macaques.
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
DOI
EISSN
Publication Date
Volume
Start / End Page
Location
Related Subject Headings
- Simian immunodeficiency virus
- Simian Immunodeficiency Virus
- Regression Analysis
- Recombinant Proteins
- Protein Binding
- Predictive Value of Tests
- Phylogeny
- Phagocytosis
- Neutralization Tests
- Mutation
Citation
Published In
DOI
EISSN
Publication Date
Volume
Start / End Page
Location
Related Subject Headings
- Simian immunodeficiency virus
- Simian Immunodeficiency Virus
- Regression Analysis
- Recombinant Proteins
- Protein Binding
- Predictive Value of Tests
- Phylogeny
- Phagocytosis
- Neutralization Tests
- Mutation